Researchers recommend that details on prescription medications received in the year before diagnosis and treatment initiation be included in clinical trials as essential baseline information.

The FDA has decided not to approve glofitamab plus gemcitabine and oxaliplatin to treat certain patients with relapsed/refractory DLBCL.

Resources available to clinical research physicians and the expectations placed upon these individuals vary across cancer cancers, data suggest.

Patients said they were less likely to book an appointment with physicians who use AI in their practice. New research suggests that patients perceive physicians as less competent, trustworthy, and ...